Results - Announcements
Ind-Swift Laboratories Ltd share price inched up 3.04% to Rs 379.45 after the company's net profit soared by 38.99% to Rs 34.15 crore, while revenue from operations increased sharply by 25.60% to Rs 240.46 crore in Q3FY26 over Q2FY26.
The market capitalization of Pharmaceuticals industry group stocks on BSE stood at Rs 27.58 lakh crore, rising 4.24%. It has marginally improved by 3.87% over last one week and crept higher by 0.06% in last one month while the market capitalization of Ind-Swift Laboratories Ltd has improved by 9.60% and 68.79% in the same period respectively.
Profit before tax (PBT) of Ind-Swift Laboratories Ltd stood at Rs 43.38 crore in Q3 FY26, expanding by 319.54% year-on-year, and surging by 33.23% quarter-on-quarter. EBITDA came in at Rs 38 crore, crashing by 962.41% YoY and jumping 46.86% sequentially.
Total expenses surged 22.45% to Rs 202.77 crore in Q3FY26 over Q3FY25. During the quarter, cost of materials consumed stood at Rs 92.87 crore, increasing 13.59% YoY, while employee benefits expense was at Rs 37.97 crore, softening 4.02% YoY.
For the TTM ended FY26, revenue from operations advanced 15.56% to Rs 649.14 crore, while net profit tanked by 82.82% to Rs 43.03 crore, compared to previous TTM. EBITDA tumbled by 9564% to Rs 0.16 crore, and PBT plunged by 80.31% to Rs 50.76 crore compared to previous TTM.
The company's consolidated net cash flow from operating activities stood at Rs 69.88 crore in FY26, as against Rs 28.69 crore in FY25.
Ind-Swift Laboratories Ltd surged by 267.15% in last one year, significantly outperforming the benchmark BSE Sensex which has reduced by 13.45% during the same period.